Ser184

Site Information
KELARQIsFKAEVNS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 465537
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ) , mutation of modification site ( 5 ) , western blotting ( 5 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 , 7 ) , 3T3 (fibroblast) [CDC42 (human), transfection] ( 6 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 6 ) , 3T3 (fibroblast) ( 6 , 27 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , brain ( 22 , 23 ) , C2C12 (myoblast) ( 19 ) , heart ( 21 , 25 , 26 ) , HEK293T (epithelial) ( 5 ) , HL-1 (myocyte) ( 4 ) , liver ( 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 24 ) , liver [leptin (mouse), homozygous knockout] ( 8 ) , RAW 264.7 (macrophage) ( 3 )

In vivo Characterization

Methods used to characterize site in vivo:

immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ) , mutation of modification site ( 5 ) , western blotting ( 5 )

Relevant cell line - cell type - tissue:

'3T3-L1, differentiated' (adipocyte) ( 2 , 7 ) , 3T3 (fibroblast) [CDC42 (human), transfection] ( 6 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 6 ) , 3T3 (fibroblast) ( 6 , 27 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , brain ( 22 , 23 ) , C2C12 (myoblast) ( 19 ) , heart ( 21 , 25 , 26 ) , HEK293T (epithelial) ( 5 ) , HL-1 (myocyte) ( 4 ) , liver ( 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 24 ) , liver [leptin (mouse), homozygous knockout] ( 8 ) , RAW 264.7 (macrophage) ( 3 )

Upstream Regulation
Regulatory protein:	KRas (mouse) ( 6 )
Putative in vivo kinases:	MAPKAPK2 (mouse) ( 5 )
Kinases, in vitro:	MAPKAPK2 (mouse) ( 5 )
Treatments:	insulin ( 7 ) , LPS ( 5 ) , LY294002 ( 7 ) , MK-2206 ( 7 )

Downstream Regulation
Effects of modification on biological processes:	translation, induced ( 5 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 28852199 Curated Info
2	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
3	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
4	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
5	Menon MB, et al. (2013) Endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 is a novel substrate of MK2 (MAPKAP kinase-2) involved in MK2-mediated TNFα production. Biochem J 456, 163-72 24020373 Curated Info
6	Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80 23608596 Curated Info
7	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
8	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
9	Possemato A (2009) CST Curation Set: 8043; Year: 2011; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
10	Possemato A (2009) CST Curation Set: 8042; Year: 2011; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
11	Possemato A (2009) CST Curation Set: 8044; Year: 2009; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
12	Possemato A (2009) CST Curation Set: 8047; Year: 2009; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
13	Guo A (2009) CST Curation Set: 7801; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
14	Guo A (2009) CST Curation Set: 7790; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
15	Guo A (2009) CST Curation Set: 7772; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
16	Guo A (2009) CST Curation Set: 7769; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
17	Guo A (2009) CST Curation Set: 7767; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
18	Guo A (2009) CST Curation Set: 7768; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
19	Possemato A (2008) CST Curation Set: 5258; Year: 2008; Biosample/Treatment: cell line, C2C12/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
20	Possemato A (2008) CST Curation Set: 3855; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
21	Possemato A (2008) CST Curation Set: 3846; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
22	Possemato A (2008) CST Curation Set: 3851; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
23	Possemato A (2008) CST Curation Set: 3854; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
24	Possemato A (2008) CST Curation Set: 3821; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
25	Possemato A (2008) CST Curation Set: 3820; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
26	Possemato A (2007) CST Curation Set: 3394; Year: 2007; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
27	Farnsworth C (2006) CST Curation Set: 1141; Year: 2006; Biosample/Treatment: cell line, 3T3/0.5% serum &'\|\|' TPA; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info